Alisol B 23-acetate protects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated regulation of transporters and enzymes involved in bile acid homeostasis

Toxicology and Applied Pharmacology

Volumn 283, Issue 3, 2015, Pages 178-186

  Meng, Qiang ^a   Chen, Xin Li ^a   Wang, Chang Yuan ^a   Liu, Qi ^a   Sun, Hui Jun ^a   Sun, Peng Yuan ^a   Huo, Xiao Kui ^a   Liu, Zhi Hao ^a   Yao, Ji Hong ^a   Liu, Ke Xin ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

Alisol B 23 acetate; ANIT; Enzymes; FXR; Liver injury; Transporters

Indexed keywords

1 NAPHTHYL ISOTHIOCYANATE; ALANINE AMINOTRANSFERASE; ALISOL B 23 ACETATE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILE SALT EXPORT PUMP; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450; CYTOCHROME P450 2B10; CYTOCHROME P450 3A11; CYTOCHROME P450 8B1; FARNESOID X RECEPTOR; GAMMA GLUTAMYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GUGGULSTERONE; HYDROXYSTEROID SULFOTRANSFERASE; HYDROXYSTEROID SULFOTRANSFERASE 2A1; LIVER PROTECTIVE AGENT; LUCIFERASE; MESSENGER RNA; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 3; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 2; SODIUM BILE ACID COTRANSPORTER; TRITERPENOID; UNCLASSIFIED DRUG; ALISOL B 23-ACETATE; CARRIER PROTEIN; CELL RECEPTOR; CHOLEST 4 EN 3 ONE; FARNESOID X-ACTIVATED RECEPTOR; NUCLEAR RECEPTOR SUBFAMILY 0, GROUP B, MEMBER 2; PROTECTIVE AGENT;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID BLOOD LEVEL; BILE ACID HOMEOSTASIS; BILE ACID SYNTHESIS; BILIRUBIN BLOOD LEVEL; CONJUGATION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG UPTAKE; ENZYME ACTIVITY; EXPERIMENTAL LIVER INJURY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENE MUTATION; HEPG2 CELL LINE; HISTOPATHOLOGY; HOMEOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAHEPATIC CHOLESTASIS; LIVER CELL; LIVER HISTOLOGY; LIVER PROTECTION; LIVER TOXICITY; LUCIFERASE ASSAY; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; REPORTER GENE; TRANSACTIVATION; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL PROTECTION; CHOLESTASIS, INTRAHEPATIC; DISEASE MODEL; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; LIVER; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TIME;

MUS;

1-NAPHTHYLISOTHIOCYANATE; ANIMALS; BILE ACIDS AND SALTS; CHOLESTASIS, INTRAHEPATIC; CHOLESTENONES; CYTOPROTECTION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HEP G2 CELLS; HOMEOSTASIS; HUMANS; LIVER; MALE; MEMBRANE TRANSPORT PROTEINS; MICE, INBRED C57BL; PROTECTIVE AGENTS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION;

EID: 84922375131     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2015.01.020     Document Type: Article

References (38)

1. Alrefai W.A., Gill R.K. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm. Res. 2007, 24:1803-1823.
2. Bechmann L.P., Kocabayoglu P., Sowa J.P., Sydor S., Best J., Schlattjan M., Beilfuss A., Schmitt J., Hannivoort R.A., Kilicarslan A., Rust C., Berr F., Tschopp O., Gerken G., Friedman S.L., Geier A., Canbay A. Free fatty acids repress small heterodimer partner (SHP) activation and adiponectin counteracts bile acid-induced liver injury in superobese patients with nonalcoholic steatohepatitis. Hepatology 2013, 57:1394-1406.
3. Bull L.N., Vargas J. Serum bile acids in intrahepatic cholestasis of pregnancy: not just a diagnostic test. Hepatology 2014, 59:1220-1222.
4. Conrad E., Resch T.K., Gogesch P., Kalinke U., Bechmann I., Bogdan C., Waibler Z. Protection against RNA-induced liver damage by myeloid cells requires type I interferon and IL-1 receptor antagonist in mice. Hepatology 2014, 59:1555-1563.
5. Csanaky I.L., Lu H., Zhang Y., Ogura K., Choudhuri S., Klaassen C.D. Organic anion-transporting polypeptide 1b2 (Oatp1b2) is important for the hepatic uptake of unconjugated bile acids: studies in Oatp1b2-null mice. Hepatology 2011, 53:272-281.
6. Cui Y.J., Aleksunes L.M., Tanaka Y., Goedken M.J., Klaassen C.D. Compensatory induction of liver efflux transporters in response to ANIT-induced liver injury is impaired in FXR-null mice. Toxicol. Sci. 2009, 110:47-60.
7. Diao M., Li L., Zhang J.S., Ye M., Cheng W. Laparoscopic cholecystocolostomy: a novel surgical approach for the treatment of progressive familial intrahepatic cholestasis. Ann. Surg. 2013, 258:1028-1033.
8. Dietrich C.G., Ottenhoff R., de Waart D.R., Oude Elferink R.P. Role of MRP2 and GSH in intrahepatic cycling of toxins. Toxicology 2001, 167:73-81.
9. Forman B.M., Goode E., Chen J., Oro A.E., Bradley D.J., Perlmann T., Noonan D.J., Burka L.T., McMorris T., Lamph W.W., Evans R.M., Weinberger C. Identification of a nuclear receptor that is activated by farnesol metabolites. Cell 1995, 81:687-693.
10. Geenes V., Chappell L.C., Seed P.T., Steer P.J., Knight M., Williamson C. Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study. Hepatology 2014, 59:1482-1491.
11. Hirschfield G.M., Heathcote E.J., Gershwin M.E. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology 2010, 139:1481-1496.
12. Hirschfield G.M., Chapman R.W., Karlsen T.H., Lammert F., Lazaridis K.N., Mason A.L. The genetics of complex cholestatic disorders. Gastroenterology 2013, 144:1357-1374.
13. Huang W., Ma K., Zhang J., Qatanani M., Cuvillier J., Liu J., Dong B., Huang X., Moore D.D. Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration. Science 2006, 312:233-236.
14. Hur J.M., Choi J.W., Park J.C. Effects of methanol extract of Alisma orientale rhizome and its major component, alisol B 23-acetate, on hepatic drug metabolizing enzymes in rats treated with bromobenzene. Arch. Pharm. Res. 2007, 30:1543-1549.
15. Jean P.A., Roth R.A. Naphthylisothiocyanate disposition in bile and its relationship to liver glutathione and toxicity. Biochem. Pharmacol. 1995, 50:1469-1474.
16. Ji F., Deng H., Li Z. Eltrombopag for thrombocytopenic patients with hepatitis C virus infection and cirrhosis. Gastroenterology 2014, 147:253-254.
17. Jiang Z.Y., Zhang X.M., Zhang F.X., Liu N., Zhao F., Zhou J., Chen J.J. A new triterpene and anti-hepatitis B virus active compounds from Alisma orientalis. Planta Med. 2006, 72:951-954.
18. Jin H.G., Jin Q., Ryun Kim A., Choi H., Lee J.H., Kim Y.S., Lee D.G., Woo E.R. A new triterpenoid from Alisma orientale and their antibacterial effect. Arch. Pharm. Res. 2012, 35:1919-1926.
19. Kong B., Wang L., Chiang J.Y., Zhang Y., Klaassen C.D., Guo G.L. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012, 56:1034-1043.
20. Lin H.R. Triterpenes from Alisma orientalis act as farnesoid X receptor agonists. Bioorg. Med. Chem. Lett. 2012, 22:4787-4792.
21. Mencarelli A., Renga B., Palladino G., Distrutti E., Fiorucci S. The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. Biochem. Pharmacol. 2009, 78:1214-1223.
22. Ohta Y., Kongo-Nishimura M., Imai Y., Kitagawa A. Melatonin attenuates disruption of serum cholesterol status in rats with a single alpha-naphthylisothiocyanate treatment. J. Pineal Res. 2007, 42:159-165.
23. Parrilla P., Robles R., Varo E., Jimenez C., Sanchez-Cabus S., Pareja E. Liver transplantation for bile duct injury after open and laparoscopic cholecystectomy. Br. J. Surg. 2014, 101:63-68.
24. Pircher P.C., Kitto J.L., Petrowski M.L., Tangirala R.K., Bischoff E.D., Schulman I.G., Westin S.K. Farnesoid X receptor regulates bile acid-amino acid conjugation. J. Biol. Chem. 2003, 278:27703-27711.
25. Regev A. Drug-induced liver injury and drug development: industry perspective. Semin. Liver Dis. 2014, 34:227-239.
26. Regev A., Bjornsson E.S. Drug-induced liver injury: morbidity, mortality, and Hy's law. Gastroenterology 2014, 147:20-24.
27. Rudich N., Zamir G., Pappo O., Shlomai Z., Faroja M., Weiss I.D., Wald H., Galun E., Peled A., Wald O. Focal liver necrosis appears early after partial hepatectomy and is dependent on T cells and antigen delivery from the gut. Liver Int. 2009, 29:1273-1284.
28. Schaap F.G., Trauner M., Jansen P.L. Bile acid receptors as targets for drug development. Nat. Rev. Gastroenterol. Hepatol. 2014, 11:55-67.
29. Staudinger J.L., Woody S., Sun M., Cui W. Nuclear-receptor-mediated regulation of drug- and bile-acid-transporter proteins in gut and liver. Drug Metab. Rev. 2013, 45:48-59.
30. Stone A., Chau C., Eaton C., Foran E., Kapur M., Prevatt E., Belkin N., Kerr D., Kohlin T., Williamson P. Biochemical characterization of P4-ATPase mutations identified in patients with progressive familial intrahepatic cholestasis. J. Biol. Chem. 2012, 287:41139-41151.
31. Tong S., Li J. Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning?. Gastroenterology 2014, 146:902-905.
32. Vanwijngaerden Y.M., Wauters J., Langouche L., Vander Perre S., Liddle C., Coulter S., Vanderborght S., Roskams T., Wilmer A., Van den Berghe G., Mesotten D. Critical illness evokes elevated circulating bile acids related to altered hepatic transporter and nuclear receptor expression. Hepatology 2011, 54:1741-1752.
33. Wagner M., Zollner G., Trauner M. Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. Semin. Liver Dis. 2010, 30:160-177.
34. Wang C., Zhang J.X., Shen X.L., Wan C.K., Tse A.K., Fong W.F. Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate. Biochem. Pharmacol. 2004, 68:843-855.
35. Wang L., Wang J., Shi Y., Zhou X., Wang X., Li Z., Huang X., Han Z., Li T., Wang M., Wang R., Fan D., Han Y. Identification of a primary biliary cirrhosis associated protein as lysosome-associated membrane protein-2. J. Proteomics 2013, 91:569-579.
36. Xu Y.H., Zhao L.J., Li Y. Alisol B acetate induces apoptosis of SGC7901 cells via mitochondrial and phosphatidylinositol 3-kinases/Akt signaling pathways. World J. Gastroenterol. 2009, 15:2870-2877.
37. Yang H., Ramani K., Xia M., Ko K.S., Li T.W., Oh P., Li J., Lu S.C. Dysregulation of glutathione synthesis during cholestasis in mice: molecular mechanisms and therapeutic implications. Hepatology 2009, 49:1982-1991.
38. Zimmers T.A., McKillop I.H., Pierce R.H., Yoo J.Y., Koniaris L.G. Massive liver growth in mice induced by systemic interleukin 6 administration. Hepatology 2003, 38:326-334.